Literature DB >> 11901101

Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).

Ailan Guo1, William Marinaro, Peidi Hu, Patrick J Sinko.   

Abstract

Multidrug resistance conferred to cancer cells is often mediated by the expression of efflux transporter "pumps". It is also believed that many of the same transporters are involved in drug efflux from numerous normal endothelial and epithelial cell types in the intestine, brain, kidney, and liver. Etoposide transport kinetics were characterized in Caco-2 cells and in well established Madin-Darby canine kidney (MDCKII) cell lines that were stably-transfected with a human cDNA encoding P-glycoprotein (Pgp), human multidrug resistance protein (MRP1), or the canalicular multispecific organic anion (cMOAT) transporters to determine the roles of these transporters in etoposide efflux. Etoposide transport kinetics were concentration-dependent in the MDCKII-MDR1 and MDCKII-cMOAT cells. The apparent secretory Michaelis constant (Km) and carrier-mediated permeability (Pc) values for Pgp and cMOAT were 254.96 +/- 94.39 microM and 5.96 +/- 0.41 x 10(-6) cm/s and 616.54 +/- 163.15 microM and 1.87 +/- 0.10 x 10(-5) cm/s, respectively. The secretory permeability of etoposide decreased significantly in the basal to apical (B to A) (i.e., efflux) direction, whereas the permeability increased 2.3-fold in the apical to basal (A to B) direction in MDCKII-MDR1 cells in the presence of elacridar (GF120918). Moderate inhibition of etoposide efflux by leukotriene C4 (LTC4) was observed in MDCKII-cMOAT cells. Furthermore, etoposide inhibited LTC4 efflux, confirming the involvement of cMOAT. The flux of etoposide in MDCKII-MRP1 cells was similar to that in MDCKII/wt control cells. The current results demonstrate that the secretory transport mechanism of etoposide involves multiple transporters, including Pgp and cMOAT but not MRP1. These results demonstrate that Pgp and cMOAT are involved in the intestinal secretory transport of etoposide. Since the intestinal secretion of etoposide was previously reported in the literature, it also suggests that they may be involved in the in vivo intestinal secretion of etoposide; however, mechanistic in vivo studies are required to confirm this.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11901101     DOI: 10.1124/dmd.30.4.457

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  20 in total

1.  Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II.

Authors:  Xia Xue; Xian-Jun Qu; Zu-Hua Gao; Cui-Cui Sun; Hui-Ping Liu; Cui-Rong Zhao; Yan-Na Cheng; Hong-Xiang Lou
Journal:  Invest New Drugs       Date:  2010-10-06       Impact factor: 3.850

2.  Ibuprofen is a non-competitive inhibitor of the peptide transporter hPEPT1 (SLC15A1): possible interactions between hPEPT1 substrates and ibuprofen.

Authors:  Diana Højmark Omkvist; Birger Brodin; Carsten Uhd Nielsen
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

Review 3.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

4.  Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.

Authors:  R A B van Waterschoot; R ter Heine; E Wagenaar; C M M van der Kruijssen; R W Rooswinkel; A D R Huitema; J H Beijnen; A H Schinkel
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

5.  Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance.

Authors:  Deep Kwatra; Ramya Krishna Vadlapatla; Aswani Dutt Vadlapudi; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2010-05-24       Impact factor: 5.875

6.  Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells.

Authors:  C Fahrmayr; J König; D Auge; M Mieth; M F Fromm
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

7.  An electrically tight in vitro blood-brain barrier model displays net brain-to-blood efflux of substrates for the ABC transporters, P-gp, Bcrp and Mrp-1.

Authors:  Hans Christian Helms; Maria Hersom; Louise Borella Kuhlmann; Lasina Badolo; Carsten Uhd Nielsen; Birger Brodin
Journal:  AAPS J       Date:  2014-06-17       Impact factor: 4.009

8.  Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.

Authors:  Rachael E Hawtin; David E Stockett; Jo Ann W Byl; Robert S McDowell; Tan Nguyen; Michelle R Arkin; Andrew Conroy; Wenjin Yang; Neil Osheroff; Judith A Fox
Journal:  PLoS One       Date:  2010-04-15       Impact factor: 3.240

9.  Species difference in intestinal absorption mechanism of etoposide and digoxin between cynomolgus monkey and rat.

Authors:  T Nishimura; Y Kato; N Amano; M Ono; Y Kubo; Y Kimura; H Fujita; A Tsuji
Journal:  Pharm Res       Date:  2008-07-15       Impact factor: 4.200

Review 10.  Pharmacokinetic optimisation of treatment with oral etoposide.

Authors:  Giuseppe Toffoli; Giuseppe Corona; Barbara Basso; Mauro Boiocchi
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.